Evidence map›Paper›PMID 39266636›Full record

ArticleScientific reports2024

A pharmacovigilance study on clinical factors of active vitamin D

Yuki Kawai, Kazushi Uneda, Satoshi Miyata, Ayana Kunii, Shohei Nagayama, Kenji Baba, Tamio Iwamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuki KawaiTeikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-Ku, Tokyo, 173-8605, Japan. t176015a@yokohama-cu.ac.jp.
Kazushi UnedaDepartment of Kampo Medicine, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
Satoshi MiyataTeikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-Ku, Tokyo, 173-8605, Japan.
Ayana KuniiDepartment of Nephrology and Hypertension, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
Shohei NagayamaDepartment of Nephrology and Hypertension, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
Kenji BabaDepartment of Nephrology and Hypertension, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.
Tamio IwamotoDepartment of Nephrology and Hypertension, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) due to vitamin D therapy for osteoporosis is encountered in clinical practice, but epidemiological studies are scarce. We aimed to determine the association between AKI and vitamin D therapy and to identify risk factors for AKI using the Japanese Adverse Drug Event Report database. We used reporting odds ratios (RORs) to detect signals and evaluate risk factors using multiple logistic regression analysis. Among 298,891 reports from April 2004 to September 2023, 1071 implicated active vitamin D

Indexed as

Acute Kidney InjuryAdverse Drug Reaction Reporting SystemsCholecalciferolDatabases, FactualPharmacovigilanceAdultAgedAged, 80 and overFemaleHumansHydroxycholecalciferolsJapanMaleMiddle AgedOsteoporosisRisk FactorsalfacalcidolCholecalciferoleldecalcitolHydroxycholecalciferolsVitamin DActive vitamin D3 analogAcute kidney injuryAlfacalcidolCalcitriolEldecalcitol

Identifiers

PMID39266636
PMCPMC11393075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.